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Memorymutant human amyloid precursor protein (APP) develop an age-dependent
amyloid pathology and memory deﬁcits, but no overt neuronal loss. Here, in mice overexpressing wild-type
human APP (hAPPwt) we found an early memory impairment, particularly in the water maze and to a lesser
extent in the object recognition task, but β-amyloid peptide (Aβ42) was barely detectable in the
hippocampus. In these mice, hAPP processing was basically non-amyloidogenic, with high levels of APP
carboxy-terminal fragments, C83 and APP intracellular domain. A tau pathology with an early increase in the
levels of phosphorylated tau in the hippocampus, a likely consequence of enhanced ERK1/2 activation, was
also observed. Furthermore, these mice presented a loss of synapse-associated proteins: PSD95, AMPA and
NMDA receptor subunits and phosphorylated CaMKII. Importantly, signs of neurodegeneration were found in
the hippocampal CA1 subﬁeld and in the entorhinal cortex that were associated to a marked loss of MAP2
immunoreactivity. Conversely, in mice expressing mutant hAPP, high levels of Aβ42 were found in the
hippocampus, but no signs of neurodegeneration were apparent. The results support the notion of Aβ-
independent pathogenic pathways in Alzheimer's disease.
© 2008 Elsevier Inc. All rights reserved.IntroductionAlzheimer's disease (AD) is a progressive neurodegenerative
disorder usually characterized by two histopathological hallmarks,
amyloid plaques, mainly composed of the β-amyloid (Aβ) peptide,
and intracellular neuroﬁbrillary tangles, comprising aggregates of
hyperphosphorylated protein tau. Other neuropathological hall-
marks, early synaptic dysfunction and selective neuronal loss, are
nowadays considered the best correlate of cognitive decline in AD
(Selkoe, 2002; Walsh and Selkoe, 2004). According to the β-amyloid
hypothesis, Aβ is the initiating cause of AD. This peptide is
proteolytically generated from the larger amyloid precursor protein
(APP) that is cleaved by β-secretase releasing a soluble fragment
(sAPPβ) and a carboxy-terminal fragment (CTF), C99, within the
membrane. The γ-secretase complex cleaves the latter fragment
releasing the Aβ peptide and the APP intracellular domain (AICD).
APP can be also processed by a non-amyloidogenic pathway that
includes the proteolysis of APP by α-secretase, within the Aβ region,
to generate a secreted soluble protein (sAPPα) and a CTF named C83.
Further cleavage of C83 by γ-secretase generates p3 peptide and the
AICD fragment. Different reports indicate that not only Aβ isirect.com).
l rights reserved.neurotoxic, but also the CTFs may alter neuronal survival. In
particular, the AICD, generated from C83 or C99 fragments, has
been identiﬁed in transgenic mouse brains overexpressing human
APP (hAPP) as well as in AD brain tissue and may have a critical
pathophysiological role (Passer et al., 2000; Shin et al., 2007).
Some studies have provided evidence for an intrinsic central role of
APP in the pathogenesis of AD and have suggested that this disease
may be a consequence of a disruption of APP normal function (Neve et
al., 2000). APP is not only important for CNS maturation but plays also
a role in cell contact and adhesion, in neuronal morphogenesis, in the
maintenance of synaptic transmission and plasticity and may even
induce a neurotrophic effect (Alpár et al., 2006; Priller et al., 2006; Oh
et al., 2008). Accordingly, APP knockout mice develop behavioral and
cognitive impairment (Dawson et al., 1999; Phinney et al., 1999).
Despite the physiological role of APP, several studies have shown that
APP overexpression may lead to an increased generation of toxic
derivatives, Aβ peptide and/or CTFs. Moreover, APP overproduction,
either as a result of genomic locus duplication or altered regulatory
sequences in the APP promoter region, leads to early-onset AD in
humans (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006).
Several transgenic mouse models for AD carrying mutations of
hAPP, presenilins, tau or different combinations have been generated
for the production of an Alzheimer-type neuropathology (Van Dam
and De Deyn, 2006). However, a completemousemodel recapitulating
all aspects of the disease has not yet been produced. In transgenic
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deﬁcits and histological alterations are due to mutant hAPP over-
expression or to excessive production of Aβ peptide or other APP-
derived products. Unexpectedly, we observed earlymemory deﬁcits in
mice overexpressing wild-type human APP despite almost undetect-
able Aβ42 levels in the hippocampus and we explored possible
pathogenic mechanisms involved in such a cognitive impairment. We
here show that overexpression of wild-type APP may promote Aβ-
independent pathogenic pathways resulting in signs of neurodegen-
eration in the hippocampus and entorhinal cortex.
Materials and methods
Transgenic mice
Transgenic hAPPwt mice overexpressing humanwild-type amyloid
precursor protein (line I5) were used in this study and also, in some
experiments, hAPPswe-ind mice overexpressing hAPP with the Swedish
(K670N/M671L) and Indiana (V717F) familial AD mutations (line J20;
numbers refer to amino acids in APP770). In both lines, neuronal
expression of hAPP was directed by the PDGF β-chain promoter. hAPP
expression was approximately the same in both transgenic lines
(Mucke et al., 2000). The mice were on an inbred C57BL/6J genetic
background. Animals were housed four-ﬁve per cage with free access
to food and water and maintained in a temperature-controlled
environment on a 12 h light/dark cycle. All procedures were carried
out in accordance with European and Spanish regulations (86/609/
CEE; RD1201/2005). This study was approved by the Ethical
Committee of the University of Navarra (no. 018/05).
Behavioral procedures
Groups of 5-month-old hAPPwt and non transgenic littermates,
underwent spatial reference learning andmemory in theMorris water
maze (MWM) test, a hippocampus-dependent learning task. Themaze
was a circular tank (diameter 1.45 m) ﬁlled with water at 20 °C. Mice
underwent visible-platform training for three consecutive days (8
trials/day), and were allowed to swim to a raised platform (diameter
10 cm) located above the water in the same position over trials.
Hidden-platform training was conducted over 9 consecutive days (4
trials/day). Mice had 60 s to ﬁnd a hidden platform submerged 1 cm
beneath the surface of the water and invisible to the mice while
swimming. Several large visual cues were placed in the room to guide
the mice to the hidden platform. Mice failing to reach the platform
were guided onto it. All the animals were allowed to rest on the
platform for 20 s and then removed from the platform and returned to
their home cage. At the beginning of 4th, 7th, and 9th day of the task, a
probe trial in which the platform was removed from the pool was
conducted, and the mice were permitted to search the platform for
60 s. All trials were monitored by a camera using an HVS water maze
program for analyses of escape latencies and percent time spent in
each quadrant of the pool during probe trials (analysis program
Ethovision, Wageningen, The Netherlands). Mice that were unable to
reach the visible-platform or mice exhibiting abnormal swimming
patterns or persistent ﬂoating were excluded from data analyses.
The apparatus for the object recognition test consisted of a dark
open box (50×35×50 cm high), illuminated by a 60 W lamp
suspended 120 cm above the box. The different objects consisted in
red rectangular prisms (2×2×8 cm high) and white pyramids
(5×5×5 cm high) among others. These objects could not be displaced
by the mice. In the week preceding testing, the animals were handled
daily and adapted to the room in which the behavioral procedures
were performed. The object recognition test was performed as
described elsewhere (Ennaceur and Delacour, 1988; Schiapparelli et
al., 2006) with minor modiﬁcations. One h before testing, the mice
were allowed to explore the apparatus without objects for 5min. Afterhabituation, two familiarization sessions were given (T1 and T2,
10min apart), inwhich the animals were left to explore for 10min two
identical objects that were placed in opposite sides of the apparatus
10 cm from the side wall. The choice trial (T3), in which memory
retention was tested, was given 24 h after T2. In this session, two
objects were presented, one of the objects used in familiarization
session (T1 and T2) and other different in shape and colour; therefore
the mice were re-exposed to a familiar (F) and a novel object (N).
Explorationwas deﬁned as directing the nose to an object at a distance
≤2 cm and/or touching the object with the nose. To avoid the presence
of olfactory trails, the apparatus and the objects were thoroughly
cleaned after each trial. The time spent by the animals in exploring
each object was recordedmanually by using a stopwatch. The reaction
to a novel object during T3 was measured by calculating the
discrimination ratio (D): time spent exploring the novel object over
total exploration time. Consequently, a ratio of 0.5 reﬂects equal
exploration of the familiar and the novel object, indicating no learning
retention.
Determination of Aβ levels
Hippocampal Aβ42 was measured by using a sensitive sandwich
ELISA kit from Biosource (Camarillo, CA, USA). In brief, hippocampus
was weighed and homogenized in 300 μl of ice-cold guanidine buffer
(5 M guanidine HCl/50 mM Tris HCl pH 8.0). The homogenates were
mixed for 4 h at room temperature and 10 μl were diluted 1:20 in
Dulbecco's phosphate buffered saline containing 5% BSA and 0.03%
Tween-20 (DPBS-BSAT) supplemented with protease inhibitor cock-
tail (Complete™ Protease Inhibitor Cocktail, Roche Diagnostics,
Mannheim, Germany) followed by centrifugation at 16,000 g for
20 min at 4 °C. Fifty microliters of this supernatant were loaded
directly onto ELISA plates in duplicate and manufacturer instructions
were followed. The Aβ standards were prepared in a buffer with the
same composition of ﬁnal hippocampal samples (0.25 M guanidine
HCl/2.5 mM Tris HCl pH 8.0 in DPBS-BSAT).
Production of protein extracts
For APP carboxy-terminal fragments determination, the hippo-
campus was homogenized in a buffer containing SDS 2%, Tris–HCl
(10 mM, pH 7.4), protease inhibitors (Complete™ Protease Inhibitor
Cocktail, Roche) and phosphatase inhibitors (0.1 mM Na3VO4, 1 mM
NaF). The homogenates were sonicated for 2 min and centrifuged at
100,000 g for 1 h. Aliquots of the supernatant were frozen at −80 °C
and protein concentration was determined by the Bradford method
using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). For some
experiments, equal amounts of protein (350 μg) were treated with
hexaﬂuoroisopropanol (HFIP, Sigma, Germany) to a ﬁnal concentra-
tion of 30% and the samples incubated for 1 h at 30 °C. These HFIP
treated extracts were then used for Western blot analysis.
To obtain the membrane-enriched protein fraction (P2 membrane
proteins), a previously describedmethod (Dunah et al., 2000) was used.
The hippocampus was homogenized in ice-cold Tris–EDTA buffer
(10 mM Tris–HCl and 5 mM EDTA, pH 7.4), containing 320 mM sucrose
and the protease and phosphatase inhibitors previously described. The
tissuehomogenatewas centrifuged at 700 g for 10min. The supernatant
was centrifuged again at 37,000 g for 40min at 4 °C. The pellet (P2) was
resuspended in 10 mM Tris–HCl buffer (pH 7.4), containing the enzyme
inhibitor mixture described above. In both cases, protein concentration
was determined (Bio-Rad protein assay) and aliquots were stored at
−80 °C until used. For Western blot analysis, aliquots of the P2
membrane fraction were solubilized by adding 0.1 volume of 10%
sodium deoxycholate in 500 mM Tris–HCl buffer (pH 9). The samples
were incubated for 30 min at 36 °C and diluted by adding 0.1 vol of
500 mM Tris–HCl (pH 9)/1% Triton X-100. After a centrifugation at
37,000 g for 10 min at 4 °C, the supernatant was frozen at −80 °C.
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For Western blot analysis of APP-derived fragments, aliquots of the
protein extracts were mixed with XT sample buffer™ plus XT reducing
agent™ or Tricine sample buffer™ (Bio-Rad) and boiled for 5 min.
Proteins were separated in a Criterion™ precast Bis–Tris 4–12%
gradient precast gel or Tris/Tricine precast gel 16.5% (Bio-Rad) and
transferred to a PVDF membrane with 0.2 μm removal rating (Hybond
LFP, Amersham Biosciences, UK). The membranes were blocked with
5% milk, 0.05% Tween-20 in TBS followed by overnight incubation
with the following primary antibodies: mouse monoclonal 6E10
(amino acids 1–17 of Aβ peptide, 1:1000, Chemicon), rabbit polyclonal
anti-APP C-terminal (amino acids 676–695) (1:2000, Sigma-Aldrich,
St. Louis, MO, USA), rabbit anti-phosphoAPP(Thr668) (1:500, Cell
Signaling Technology, Beverly, MA, USA) and mouse monoclonal anti
α-tubulin (1:10,000, Sigma).
For determination of other proteins, samples were mixed with an
equal volume of 2× Laemmli sample buffer, resolved onto SDS-
polyacrylamide gels and transferred to nitrocellulose membrane
(Hybond ECL, Amersham Biosciences). The membranes were blocked
with 5% milk, 0.05% Tween-20 in PBS or TBS followed by overnight
incubation with the following primary antibodies: monoclonal anti-
tau (clone Tau46, 1:3000, Sigma), mouse monoclonal PHF-1 (1:100, a
gift from Dr. J. Avila, CBM, Madrid), rabbit polyclonal anti-ERK1/2
(1:1000, Upstate), mouse monoclonal anti-phospho ERK1/2 (1:1000,
Upstate), rabbit polyclonal anti-GSK3β(Ser9) (1:1000, Cell Signaling),
rabbit polyclonal anti-GluR1 (0.2 μg/ml, Chemicon, Temecula, CA, USA),
rabbit polyclonal anti-GluR2/3 (0.1 μg/ml, Chemicon), rabbit polyclonal
anti-NR1 (1:1000, Upstate), rabbit polyclonal anti-NR2A (1:1000,
Upstate), rabbit polyclonal anti-NR2B (1:1000, Upstate), mouse
monoclonal anti-CaMKII (1:10,000, Chemicon), mouse monoclonal
anti-phospho CaMKII(Thr286) (1:1000, Upstate), mouse monoclonal
anti-PSD95 (1:300, Chemicon) and mouse monoclonal anti α-tubulin
(1:10,000, Sigma) in the corresponding buffer.
In all cases, membranes were washed three times in PBS or PBS/
Tween20 at room temperature, and HRP-conjugated anti-rabbit or
anti-mouse antibody (Dako Denmark; dilution 1:2000) was added
and incubated for 1.5 h. Immunolabelled protein bands were
detected using an enhanced chemiluminiscence system (ECL Plus
detection system, Amersham Biosciences) followed by autoradio-
graphic exposure to Hyperﬁlm™ECL (Amersham Biosciences). The
quantiﬁcation of signals was performed using Scion Image software
(Scion Corporation) or a Storm® 860 imaging systems (Amersham
Biosciences).
Tissue processing for histochemistry
Under xylazine/ketamine anesthesia, animals were perfused
transcardially with saline and 4% paraformaldehyde in phosphate
buffer (PB). After perfusion, brains were removed, post-ﬁxed in the
same ﬁxative solution for 1 h at room temperature and cryoprotected
in 30% sucrose solution in PB overnight at 4 °C. Microtome sections
(30-μm-thick) were cut coronally through the entire hippocampus,
collected free-ﬂoating and stored in 30% ethylene glycol, 30% glycerol,
and 0.1 M PB at −20 °C until processed.
Nissl staining quantiﬁcation
Some sections were processed for histological assessment of
damage by staining with thionin (Nissl staining). Quantitative
assessment of cell density in the pyramidal layer of CA1 hippocampal
subﬁeld and in the entorhinal cortexwas performed in stained coronal
sections with a light microscope using a 4× objective and the analySIS
image system (Olympus). Video images of each region of interest were
captured on 30 μm sections, and a threshold of optical density was
obtained that discriminated staining from background. Densitometricquantiﬁcation of the percent area of CA1 covered by the pyramidal
layer or the density of cells stained along lateral sections of the
entorhinal cortex was performed using six sections per mouse (n=5).
Brain sections from mice to be compared in any given experiment
were blind coded and processed in parallel.
Immunohistochemistry
Five free ﬂoating tissue sections comprising the hippocampal
formation of ﬁve animals per group were processed for immunohis-
tochemistry. Brain sections were washed (3×10 min) with PBS 0.1 M
(pH 7.4) and incubated in blocking solution (PBS containing 0.5%
Triton X-100, 0.1% BSA and 2% normal goat serum) for 2 h at room
temperature. For 6E10 immunostaining, sections were incubated in
70% formic acid for 7 min to expose the epitope. Primary and
secondary antibodies were diluted in the blocking solution. Sections
were incubated with the primary antibodies for 24 h at 4 °C, washed
with PBS and incubated with the secondary antibodies for 2 h at room
temperature, protected from light. The primary antibodies used were:
mouse monoclonal 6E10 (amino acids 1–17 of Aβ peptide, 1:200,
Chemicon), rabbit polyclonal anti-APP-CT20 (amino acids 751–770,
1:1000, Calbiochem), monoclonal mouse anti-NeuN (1:300, Chemi-
con) and rabbit polyclonal anti-MAP2 (1:1000, Chemicon). Secondary
antibodies used were Alexa Fluor 488 goat anti-mouse, highly cross-
adsorbed, Alexa Fluor 488 goat anti-rabbit, highly cross-adsorbed, and
Alexa Fluor 546 goat anti-rabbit, highly cross-adsorbed (all 1:200,
Molecular Probes,Eugene, Oregon, USA). Sections were mounted on
super frost plus slides, air dried for 24 h, rinsed in toluene (2×5 min),
and cover-slippedwith DPXmountingmedium. To ensure comparable
immunostaining, sections were processed together under identical
conditions. For the assessment of non-speciﬁc primary immunostain-
ing, some sections from each experimental group were incubated
without the primary antibodies; in this case no immunostaining was
observed. Non-speciﬁc secondary immunostaining was also evaluated
by incubating sections with primary and its non-respective secondary
antibodies; again, no immunostaining was observed. Fluorescence
signals were detected with confocal microscope LSM 510 Meta (Carl
Zeiss, Germany); objective Plan-neoﬂuar 40×/1.3 oil DIC. Sections
were evaluated in Z-series (∼0.4 μm steps) using LSM 510 Meta
software.
Results
Memory deﬁcits in mice expressing human APP
In the Morris water maze, all experiments with transgenic mice
(hAPPwt) and non transgenic littermates were performed on a blind
basis. Only one animal, a non transgenic littermate, was excluded from
the analysis as it was unable to reach the visible-platform. No
signiﬁcant differences among groups were found during the days of
visible platform training (Fig. 1A). In the spatial component of the test
(invisible platform), there were signiﬁcant differences among groups
(Pb0.01). hAPPwt mice showed signiﬁcant deﬁcits (Pb0.05 or better)
every training day when compared to non transgenic mice (Fig. 1B). In
the probe trial which provides a putative measure of memory
retention, an impairment was found. As it has been suggested that
the sensitivity of the MWM test can be increased by giving shorter
probe trials (Gerlai, 2001), we analyzed the performance of mice
during the ﬁrst 15 s of every probe trial (Fig. 1C). ANOVA showed a
signiﬁcant difference between groups, and hAPPwt mice did not retain
a clear bias for the platform location 24 h after the last training session
on days 4, 7 and 9.
Object recognition memory was analyzed at two different ages in
transgenic mice. At early stages, 5 months of age, hAPPwt mice did not
show impaired recognition memory with a discrimination index
(DI=0.71±0.020) similar to the non-transgenic animals (DI=0.72±0.38).
Fig.1. Performance of hAPPwt transgenic mice in theMorris watermaze (5-month-old mice) and in the object recognition task (5–8-month-old mice). (A) Escape latency in the visible
platform training. No signiﬁcant differences were detected among groups on any day of training. (B) Escape latency in the invisible platform. Values aremeans±SEM (n=12). ⁎P≤0.05
or better vs. non-transgenic mice (ANOVA followed by Scheffé test), (C) Impaired spatial memory of hAPPwt mice in the three 15 s probe trials (⁎⁎⁎P≤0.001, ANOVA followed by
Scheffé test). (D) Memory deﬁcit of hAPPwt transgenic mice in the object recognition test at different ages. The familiarization (T1) and choice (T2) sessions were spaced 24 h apart.
Values are means±SEM (n=19–32 in control groups and n=11–19 in transgenic groups). ⁎⁎⁎Pb0.001 vs. non-transgenic mice (ANOVA followed by Scheffé test).
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apparent in hAPPwt mice with a discrimination index signiﬁcantly lower
than non transgenic controls (Pb0.001) (Fig. 1D). The discrimination
indexes were 0.55±0.023 for APPwt mice, and 0.77±0.032 for non-
transgenic controls.
Aβ levels in APP transgenic mice
Hippocampal levels of Aβ42 were determined in 5- and 8-month-
old hAPPwt and hAPPswe-ind mice. As shown in Fig. 2A, in the
hippocampus from animals overexpressing wild-type hAPP barely
detectable levels of Aβ42 were found whereas mice overexpressing
mutant hAPP showed elevated levels of this peptide. So it seems that
in the transgenic lines used in this study, the presence of Aβ42 is
dependent of the presence in APP of mutations related to familial AD.
Using 6E10 antibody, that recognizes the amino-terminal region of
Aβ, we performed Western-blot analysis in hippocampal protein
extracts from hAPPwt and hAPPswe-ind transgenic mice. As shown in
Fig. 2B, we detected in blots from both transgenic lines a band at
105 kDa (corresponding to human APP) and an additional band at
∼56 kDa. It is important to note that the intensity of the latter band
was lower in hAPPwt mice than in mice overexpressing mutant hAPP.
This band seems to correspond in size with the recently characterized
Aβ dodecamer, termed Aβ⁎56, which correlates with cognitive deﬁcits
in transgenic mice. To conﬁrm that this band was indeed an Aβ
oligomer, we treated the hippocampal homogenates with HFIP 30%, a
compound known to disrupt Aβ oligomers, for 1 h. As shown in Fig.
2B, after treatment with this solvent the band disappeared indicating
the depolymerization of the oligomer complex.Analysis of APP-derived carboxy-terminal fragments
We analyzed the expression of APP-derived CTFs by immunohis-
tochemical and Western blot techniques. In animals overexpressing
the human wild-type APP, using 6E10 antibody we found a moderate
labelling in neuronal cell bodies of the pyramidal cell layer of CA1
(Fig. 3A) and an intense and diffuse immunoreactivity in the cerebral
cortex and adjacent areas as well as in the hilus of dentate gyrus (not
shown). Because the antibody used in this study recognizes amino
acids 1–17 of Aβ peptide, it is difﬁcult to precise whether the
labelling corresponded to this peptide or to APP. Nevertheless, taking
into account that these mice showed virtually undetectable levels of
Aβ in the hippocampus (Fig. 2A), it is possible to suppose that the
immunoreactivity against 6E10 corresponded to APP, probably
located in neuritic processes. No 6E10 immunoreactive senile
plaques were detected in brain sections from aged hAPPwt mice
(15–20 months, not shown). When the CT-20 antibody was used, we
found a selective location in neuronal cell bodies in hAPPwt mice
(Fig. 3B). This labelling probably corresponds to the presence of
carboxy-terminal fragments derived from the processing of APP and
remaining inside the neuron.
We analyzed by Western blot the levels of the CTFs C83, C99 and
AICD in transgenic mice overexpressing hAPPwt and we found that
these mice produced much more C83 than C99 (Pb0.001) with a ratio
of 3.01±029 (Fig. 3C). This could be related to the facilitated α-
secretase metabolism of APP. In order to obtain better resolution of
small peptides derived from APP, we performed analysis by Western
blot in hippocampal extracts using Tris/tricine PAGE 16.5% gels.
Employing an antibody that recognizes the C-terminal fragment of
Fig. 2. Aβ peptides in the hippocampus of hAPPwt and hAPPswe-ind transgenic mice. (A)
Levels of Aβ42 determined by ELISA. Values are means±SEM (n=5), ⁎⁎⁎Pb0.001 vs.
hAPPwt mice (Student's t test). (B) Western blot analysis of hippocampal extracts using
6E10 antibody revealed in both transgenic cohorts a 56 kDa band that disappeared after
treatment with HFIP.
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mice a strong band, immediately below C83 carboxy-terminal
fragment at about 6 kDa molecular weight, probably corresponding
to AICD fragment (Fig. 3C).Fig. 3. Analysis of APP and APP-derived CTFs in hippocampus from transgenic hAPPwt mice.
for 6E10 (A) and CT20 antibody (B) in 8 month-old mice (scale bar=50 μm). Representative b
from APP processing and AICD fragment (C) in 5-month-old mice. Quantiﬁed values are mePhosphorylation of C83 and C99 fragments at Thr668
Given the importance of the phosphorylation status of APP-derived
CTFs, both in processing and function, we also analyzed the levels of
phosphorylated C83 and C99 at the recognized Thr668 residue. The
hAPPwt mice showed similar levels of pC99 and pC83 (Fig. 4) in spite of
the signiﬁcantly higher expression of C83. By analyzing the pC83/C83
and pC99/C99 ratios, we found that the latter was signiﬁcantly higher
(Pb0.001) in hAPPwt mice (Fig. 4).
Increased levels of phosphorylated tau in hAPPwt transgenic mice
We next explored another possible neuropathological correlate of
memory impairment in transgenic hAPPwt mice. We measured tau
phosphorylation at the epitopes recognized by the PHF-1 antibody
(phosphorylated Ser 396 and 404 according to the residue numbering
of the longest human tau isoform of 441 aa), an antibody commonly
employed in neuropathological studies, that recognizes aberrantly
hyperphosphorylated epitopes on tau. Five month-old hAPPwt and
hAPPswe-ind transgenic mice, in particular the latter line, displayed
signiﬁcantly elevated levels of phosphorylated tau as compared to
non-transgenic animals. No change in non-phosphorylated tau levels
was found (Fig. 5).
We then looked for changes in kinase activity accounting for the
enhanced tau phosphorylation. No change in GSK3β activity was
found (not shown). However the observed increase of tau phosphor-
ylation in hAPPwt mice was accompanied by activation of ERK1/2,
evaluated by measuring the levels of phosphorylated ERK1/2 which
were increased by more than three-fold (not shown). Again, total
levels of the non-phosphorylated enzyme were not modiﬁed.
Effect of wild-type hAPP overexpression on synapse-associated proteins
We analyzed the possible consequences of wild-type hAPP over-
expression on proteins directly implicated in processes of synaptic
plasticity, particularly in memory consolidation. As shown in Fig. 6, in
hAPPwt mice there was an important loss of AMPA (GluR1, GluR2/3)
and NMDA (NR1, NR2A, NR2B) receptor subunits in hippocampalRepresentative images of the immunoﬂuorescent staining in CA1 hippocampal subﬁeld
lots resulting fromWestern blotting and quantiﬁcation of C83 and C99 products derived
ans±SEM (7–8 animals per group) of optical densities (⁎⁎Pb 0.01, Student's t test).
Fig. 5. Tau hyperphosphorylation in the hippocampus from 5-month-old hAPPwt and
hAPPswe-ind transgenic mice. Values are means±SEM of optical density (n=6–14).
⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs. non-transgenic mice; †Pb0.05 vs. hAPPwt mice (ANOVA
followed by Scheffé test).
Fig. 4. Levels of CTFs (C83 and C99) phosphorylated at Thr668 in hippocampal protein
extracts from 5-month-old hAPPwt mice. Experiments were performed in duplicate.
Values are means±SEM (4–5 animals per group) of optical density. Signiﬁcant
differences: ⁎Pb0.05, ⁎⁎Pb0.01, Student's t test.
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however, GluR1 subunit was signiﬁcantly reduced but all other AMPA
and NMDA receptor subunits were not at all affected (not shown). We
also found in hAPPwt mice a signiﬁcant decrease in the activity of
CaMKII, evaluated by determination of levels of pCaMKII (Thr286),
which was not accompanied by changes in total levels of the enzyme
(Fig. 6). On the other hand, reduced levels of the postsynaptic marker
PSD95 were apparent in these mice. These ﬁndings, together with the
decreased immunoreactivity for the dendritic marker MAP2 (see
below), indicate an important alteration in synaptic function in mice
overexpressing wild-type hAPP.
Signs of neurodegeneration in hAPPwt transgenic mice
To assess the extent of neurodegenerative alterations in hAPPwt
mice, histological analysis was performed using stains and anti-
bodies against markers of neuronal integrity in areas sensitive to
neuronal loss in AD such as the hippocampus and the entorhinal
cortex. Compared with non-transgenic controls and also with
transgenic mice expressing mutant APP, hAPPwt mice displayed
decreased Nissl staining in CA1, suggesting a reduced cell density,
quite clear at the early age of 5 months (data not shown), and
evident at 8 months (Figs. 7A–C). This decrease seems to correspond
to a loss of neurons in this area evidenced by the decreased level of
immunoreactivity for the neuronal-speciﬁc marker NeuN (small box
in Figs. 7A–C). This apparent cell density decrease was also present
in the entorhinal cortex of hAPPwt mice but not in transgenic mice
expressing mutant APP (Figs. 7D–F). These signs of neurodegenera-
tion were associated to a marked loss of immunoreactivity for MAP2
in 8-month-old hAPPwt mice (Figs. 7G–I). Quantitative studies in the
CA1 subﬁeld and in the entorhinal cortex of hAPPwt mice revealed a
signiﬁcant percent reduction in the area of CA1 covered by thepyramidal layer and in the density of cells stained along the
entorhinal cortex (Figs. 7J, K).
Discussion
In this study, we found that transgenic mice expressing wild-type
human APP (hAPPwt) manifested multiple pathological features
including cognitive deﬁcits in two experimental tasks, Morris water
maze and object recognition, and severe histopathological abnorm-
alities affecting the cytoskeleton as well as signs of synaptic
dysfunction. Remarkably, a signiﬁcant reduction in Nissl staining in
the hippocampus and entorhinal cortex, suggesting cell loss, was also
found. These alterations were observed in the presence of almost
undetectable levels of Aβ peptide but concurredwith an early increase
in phosphorylated tau protein and elevated levels of APP-derived CTFs.
There was a difference in the onset of memory deﬁcits in hAPPwt
mice depending on the test considered, probably due to the cognitive
demand of each task and to the degree of brain region affectation.
Spatial memory performance requires a larger hippocampal integrity
than does recognition memory (Broadbent et al. 2004), whereas the
latter is more dependent on other brain regions, such as the perirhinal
cortex (Winters and Bussey 2005). We observed that spatial memory
was markedly impaired in 5 month-old animals, suggesting an early
disruption of hippocampal function. In the object recognition task,
visual discrimination memory of hAPPwt mice was also impaired but
at a later age, 8 months. In consonance with our results, pronounced
object discrimination memory impairment has been found in
different APP transgenic lines with familial AD-related mutations
(Dewachter et al., 2002; Zhang et al. 2006). In other transgenic APP
mice, spatial memory was severely affected while recognition
memory was either intact (Chen et al., 2000) or an age-dependent
decrease was found (Dodart et al., 1999).
Along with the cognitive impairment, we found that hAPPwt mice
presented cytoskeletal alterations as well as synaptic pathology, key
pathological features of Alzheimer's disease. Particularly, we found an
age-related decrease in dendritic integrity, deﬁned by MAP2 immu-
noreactivity, and reduced levels of PSD95 protein, the major
component of postsynaptic density, which is affected in AD. hAPPwt
mice also showed an increased phosphorylation of tau protein, an
event directly related to stability of cytoskeleton and associated to AD.
Fig. 6. Changes in synapse-associated proteins of 8-month-old hAPPwt mice. Values aremeans±SEM of optical density (n=5). ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 vs. non-transgenic mice
(Student's t test).
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ﬁnd changes in GSK3β activity, but high levels of activated ERK1/2, an
enzyme that phosphorylates tau at epitopes recognized by PHF1
antibody, were found in the hippocampus. Abnormal tau phosphor-
ylation occurs in a sequential manner, tau ERK1/2 sites being among
the ﬁrst to be phosphorylated (Echeverria et al., 2004). A similar
situation has been observed in the human brain, where activation of
this enzyme is associated to early tau deposition in neurons (Ferrer et
al. 2001). It seems however that abnormal tau phosphorylation is not
the primary cause for neurodegeneration as tau protein phosphoryla-
tion was still higher in hAPPswe-ind mice that did not show
neurodegeneration signs. Notably, we also found in hAPPwt mice a
signiﬁcant decrease of proteins directly implicated in processes of
synaptic plasticity, particularly memory consolidation. There was a
reduced membrane expression of NMDA and AMPA receptor subunits
which could interfere with an appropriate excitatory transmission
and, consequently, with the induction and maintenance of memory
respectively (Lu et al. 2001). Therewas also a profound decrease in Ca2+-
independent activated CaMKII in membrane preparations, without
changes in total levels of the enzyme. This protein is particularly
enriched in postsynaptic regions and has been considered a crucial
memory molecule (Fink and Meyer, 2002). All of these ﬁndings are
indicative of a synaptic dysfunction in hAPPwt mice. Furthermore,
neurons from hAPPwt mice showed a very low NeuN immunolabellingsuggesting a degenerative process. An apparent age-dependent
reduction in cell density, estimated by quantiﬁcation of Nissl stained
sections, was observed in the hippocampus and in the entorhinal
cortex. This latter ﬁnding is of particular relevance because most
currently available animal models of AD show cognitive deﬁcits and
neuropathological alterations but fail to recapitulate the extensive
neuronal loss observed in the later stages of human disease
(McGowan et al., 2006).
It is remarkable that the early cognitive impairment and neuro-
pathological alterations here found in transgenic mice overexpressing
wild-type human APP were not related to abnormal hippocampal
levels of Aβ42 peptide. In line with our ﬁndings, several other studies
have shown learning andmemory deﬁcits in animals expressing wild-
type or mutant hAPP not related to the presence of Aβ (Yamaguchi et
al., 1991; Gruart et al., 2008), and it is known that mild overexpression
of APP confers an age-dependent progressive and speciﬁc memory
impairment independent of plaque formation (Moechars et al., 1999;
Koistinaho et al., 2001). In mutant APP transgenic mice, knockout of
PS1 attenuated Aβ pathology but did not rescue cognitive deﬁcits
(Dewachter et al., 2002; Saura et al., 2005). Furthermore, different
studies have shown cognitive deﬁcits in the absence of Aβ peptide and
cognitive improvement without changes in Aβ pathology (Oddo et al.,
2006; Shioi et al., 2007). It was also recently reported that introduction
of a mutation that prevents the cleavage of APP by caspases in APP
Fig. 7. Neuropathological signs in the brains of 8-month-old hAPPwt mice. Comparative studies were performed in hAPPswe-ind mice and in non-transgenic controls. Sections were
either Nissl- stained (A–F) or immunostained with antibodies against MAP2 (G–I). For A–C and G–I, representative images are from the hippocampus, and for D–F, images are from
the entorhinal cortex. (A–C) CA1 neuronal layer showed a signiﬁcant reduction in the thickness of Nissl positive cells (dotted lines) in the hAPPwt transgenic mice along with a
reduction of NeuN-immunopositive cells (small boxes). (D–F) Nissl staining was clearly reduced in the entorhinal cortex of hAPPwt mice. (G–I) Signiﬁcant reduction in MAP2
immunostaining was also observed in the hAPPwt animals. (J–K) Quantiﬁcation of Nissl staining in hippocampus and entorhinal cortex from hAPPwt animals showed a signiﬁcant
reduction in the number of cells in both areas. Values are means±SEM of six sections analyzed per mouse (n=5). ⁎Pb0.05, ⁎⁎⁎Pb0.001 vs. non-transgenic mice (Student's t test).
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affect Aβ loading (Galvan et al. 2006). Indeed, abundant evidences
have shown that cognitive decline in AD correlates betterwith synapse
loss or tau pathology than with Aβ plaque burden (Braak and Braak,
1991; Selkoe, 2002;Walsh and Selkoe, 2004). It has beenproposed that
soluble Aβ, rather than insoluble Aβ, confers neurotoxicity and it has
been recognized that certain species of soluble Aβ, such as Aβ
oligomers, are neurotoxic and disrupt long-term potentiation. An
interesting study with Tg2576 mice overexpressing mutant hAPP
reported the presence of an Aβ 12-mer oligomer, termed Aβ⁎56,which
seems to be directly related with the appearance of cognitive deﬁcits
(Lesné et al., 2006). In hAPPwt mice, we detected by immunoblotting aweak 56-kDa band that disappeared after HFIP treatment suggesting
that this band might correspond to the Aβ⁎56 oligomer. It is to be
supposed that the barely detectable amount of Aβ42 is rapidly
polymerized. It is relevant that in hAPPswe-ind mice, showing also
cognitive impairment and minor histopathological alterations (eg
Palop et al., 2003), the ratio of levels of Aβ⁎56 oligomer vs. APP
expressionwas signiﬁcantly higher than in hAPPwtmice. It is therefore
unlikely that the very low levels of this oligomer, as compared to APP
levels, may account for the cognitive impairment and neuropatholo-
gical alterations in mice overexpressing wild-type hAPP. It is also
important to note that, according to the amyloid cascade hypothesis
(eg Citron, 2004), the abnormal hyperphosphorylation of tau in AD is a
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we found an increase in phospho-tau in the hippocampus of hAPPwt
mice not related to the presence of Aβ.
Increased APP transcriptional activity constitutes a risk factor for
AD (Sleegers et al., 2006; Brouwers et al., 2006; Theuns et al., 2006;
Guyant-Maréchal et al., 2007). Indeed, a number of reports indicate
that the amount of APP mRNA is increased in autopsied brains of AD
patients (Moir et al., 1998; Preece et al., 2004; Matsui et al., 2007) and
it is remarkable that overproduction of APP in Down's syndrome leads
to clinical AD pathology several years earlier than in the general
population (Bush and Beail, 2004; Head et al., 2007). Products derived
fromAPPmetabolism, other that Aβ peptide, in particular CTFs such as
C83, C99 and AICD, could play a crucial pathological role in AD
(Rockenstein et al., 2005). These derivatives may cause neurodegen-
eration by promoting apoptosis, alteration of actin dynamics and tau
hyperphosphorylation through the regulation of gene expression or
by a direct interaction with proteins of the cytoskeleton (Kim et al.
2003; Chang et al. 2006; Lee et al., 2006; Müller et al. 2007). Whenwe
analyzed the expression of C83 and C99 fragments in the hippocam-
pus of hAPPwt mice we found that APP processing was almost
exclusively non amyloidogenic, with high presence of the C83
fragment derived from α-secretase cleavage. Of particular relevance
is the observation that mice expressing wild-type hAPP have elevated
levels of AICD, likely derived from proteolysis of the highly expressed
C83 fragment (Waldron et al., 2008). Given the neurotoxic effects of
AICD, its presence at elevated concentrations in the hippocampus of
hAPPwt mice may be responsible, at least in part, for the pathological
alterations in these mice. We also found increased levels of
phosphorylated CTFs at Thr668 of relevance for regulation of both
APP processing and function (Lee et al., 2003; Chang et al., 2006).
Particularly, we found a high accumulation of pC83(Thr668) and also a
signiﬁcant increase of the ratio pC99/C99 in hAPPwt mice which could
facilitate the posterior cleavage by γ-secretase facilitating AICD
accumulation (Vingtdeux et al. 2005). The increased levels of
phosphorylated CTF in hAPPwt mice, could probably lead to more
AICD available to translocate to the nucleus for inducing neurodegen-
eration. In this and another related study (Rockenstein et al., 2005)
suggesting CTF neurotoxicity in the presence of low Aβ production, no
unequivocal evidence is however provided for the molecular species
causing neurodegeneration. Other possibilities remain to be explored,
in particular the dysfunction of APP signaling induced by wild-type
APP overexpression which may lead to cell cycle abnormalities and
neuronal cell death (Neve and McPhie, 2007).
Summing up, this study shows that overexpression of wild-type
hAPP in mice may recapitulate some crucial features related to
Alzheimer's disease such as cognitive impairment, cytoskeletal
pathology, synaptic dysfunction and, of particular relevance, signs of
neurodegeneration in brain regions directly related to synaptic
plasticity and memory. These alterations occur in the absence of
signiﬁcant levels of Aβ peptide and may be related to hAPP
overexpression and the corresponding generation of carboxy-terminal
derivatives. The present ﬁndings support the relevance of Aβ-
independent mechanisms in the pathogenesis of Alzheimer's disease.
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